不安障害(Anxiety Disorders):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Anxiety Disorders - Pipeline Review, H2 2014
◆商品コード:GMDHC5789IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:164
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における不安障害(Anxiety Disorders)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・不安障害(Anxiety Disorders)の概要
・不安障害(Anxiety Disorders)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・不安障害(Anxiety Disorders)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・不安障害(Anxiety Disorders)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・不安障害(Anxiety Disorders)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Anxiety Disorders – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Anxiety Disorders – Pipeline Review, H2 2014’, provides an overview of the Anxiety Disorders’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Anxiety Disorders and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Anxiety Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anxiety Disorders pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Anxiety Disorders Overview 8
Therapeutics Development 9
Pipeline Products for Anxiety Disorders – Overview 9
Pipeline Products for Anxiety Disorders – Comparative Analysis 10
Anxiety Disorders – Therapeutics under Development by Companies 11
Anxiety Disorders – Therapeutics under Investigation by Universities/Institutes 15
Anxiety Disorders – Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Anxiety Disorders – Products under Development by Companies 19
Anxiety Disorders – Products under Investigation by Universities/Institutes 22
Anxiety Disorders – Companies Involved in Therapeutics Development 23
Ache Laboratorios Farmaceuticos S/A 23
Adamed Sp. z o.o. 24
Addex Therapeutics Ltd 25
Avineuro Pharmaceuticals, Inc. 26
Azevan Pharmaceuticals, Inc. 27
Beech Tree Labs, Inc. 28
Bionomics Limited 29
Boehringer Ingelheim GmbH 30
C4X Discovery Ltd 31
Concert Pharmaceuticals, Inc. 32
Eisai Co., Ltd. 33
Eli Lilly and Company 34
F. Hoffmann-La Roche Ltd. 35
GW Pharmaceuticals plc 36
HolsboerMaschmeyer NeuroChemie GmbH 37
Johnson & Johnson 38
Merz Pharmaceuticals GmbH 39
MI.TO. Technology S.r.L. 40
Newron Pharmaceuticals S.p.A. 41
Nuvo Research Inc. 42
Omeros Corporation 43
Richter Gedeon Nyrt. 44
Rottapharm SpA 45
Sigma-Tau S.p.A. 46
SK Biopharmaceuticals Co., Ltd. 47
Suda Ltd 48
Sumitomo Dainippon Pharma Co., Ltd. 49
Trevena, Inc. 50
Anxiety Disorders – Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Target 52
Assessment by Mechanism of Action 55
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
ADN-2013 – Drug Profile 62
ADX-71441 – Drug Profile 63
ADX-88178 – Drug Profile 64
alprazolam – Drug Profile 65
AVL-5189 – Drug Profile 66
AVN-101 – Drug Profile 67
AVN-397 – Drug Profile 68
AVN-628 – Drug Profile 69
AZ-01 – Drug Profile 70
BCA-909 – Drug Profile 71
BNC-210 – Drug Profile 73
BTL-ng – Drug Profile 75
CR-5542 Series – Drug Profile 76
CTP-354 – Drug Profile 77
dipraglurant IR – Drug Profile 78
Drugs to Activate HAT for CNS Disorders – Drug Profile 79
Drugs to Inhibit Histone Deacetylase for CNS Disorders – Drug Profile 80
Drugs to Modulate NPSR for Anxiety Disorder – Drug Profile 81
Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders – Drug Profile 82
E-2508 – Drug Profile 83
itriglumide – Drug Profile 84
JNJ-31020028 – Drug Profile 85
JNJ-42165279 – Drug Profile 86
LSN-2535717 – Drug Profile 87
LY-2607540 – Drug Profile 88
midazolam hydrochloride – Drug Profile 89
MRZ-8676 – Drug Profile 91
nabiximols – Drug Profile 92
NB-51R1 – Drug Profile 95
NW-3509 – Drug Profile 96
Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders – Drug Profile 97
Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder – Drug Profile 98
PT-00114 – Drug Profile 99
PT-00121 – Drug Profile 100
PT-00211 – Drug Profile 101
PT-00411 – Drug Profile 102
RGH-618 – Drug Profile 103
Ro-646198 – Drug Profile 105
SCT-66 – Drug Profile 106
Small Molecule to Agonize mGluR2 for Anxiety Disorders – Drug Profile 107
Small Molecule to Antagonize Corticotropin-Releasing Factor 1 Receptor for Anxiety Disorders – Drug Profile 108
Small Molecule To Antagonize GPR31 for Anxiety Disorders – Drug Profile 109
Small Molecule to Target GPR83 for CNS and Immunological Disorders – Drug Profile 110
Small Molecules for Depression and Anxiety – Drug Profile 111
Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders – Drug Profile 112
Small Molecules to Activate Translocator Protein for Anxiety – Drug Profile 113
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders – Drug Profile 114
Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder – Drug Profile 115
Small Molecules to Agonize Delta Opioid Receptor for CNS Disorders – Drug Profile 116
Small Molecules to Agonize Mineralocorticoid Receptor for Depression and Anxiety – Drug Profile 117
Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders – Drug Profile 118
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders – Drug Profile 119
Small Molecules to Inhibit mGluR7 For Central Nervous System Disorders – Drug Profile 120
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy – Drug Profile 121
Small Molecules to Target Oxytocin for Autism and Anxiety Disorders – Drug Profile 122
ST-4070 – Drug Profile 123
Synthetic Peptide for Anxiety Disorders – Drug Profile 124
TPI-136117 – Drug Profile 125
VAD-1 – Drug Profile 126
VAD-2 – Drug Profile 127
YKP-3089 – Drug Profile 128
Anxiety Disorders – Recent Pipeline Updates 130
Anxiety Disorders – Dormant Projects 144
Anxiety Disorders – Discontinued Products 147
Anxiety Disorders – Product Development Milestones 150
Featured News & Press Releases 150
Appendix 158
Methodology 158
Coverage 158
Secondary Research 158
Primary Research 158
Expert Panel Validation 158
Contact Us 159
Disclaimer 159

[List of Tables]
Number of Products under Development for Anxiety Disorders, H2 2014 14
Number of Products under Development for Anxiety Disorders - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 17
Number of Products under Development by Companies, H2 2014 (Contd..1) 18
Number of Products under Development by Companies, H2 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2014 20
Comparative Analysis by Clinical Stage Development, H2 2014 21
Comparative Analysis by Early Stage Development, H2 2014 22
Comparative Analysis by Unknown Stage Development, H2 2014 23
Products under Development by Companies, H2 2014 24
Products under Development by Companies, H2 2014 (Contd..1) 25
Products under Development by Companies, H2 2014 (Contd..2) 26
Products under Investigation by Universities/Institutes, H2 2014 27
Anxiety Disorders - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2014 28
Anxiety Disorders - Pipeline by Adamed Sp. z o.o., H2 2014 29
Anxiety Disorders - Pipeline by Addex Therapeutics Ltd, H2 2014 30
Anxiety Disorders - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2014 31
Anxiety Disorders - Pipeline by Azevan Pharmaceuticals, Inc., H2 2014 32
Anxiety Disorders - Pipeline by Beech Tree Labs, Inc., H2 2014 33
Anxiety Disorders - Pipeline by Bionomics Limited, H2 2014 34
Anxiety Disorders - Pipeline by Boehringer Ingelheim GmbH, H2 2014 35
Anxiety Disorders - Pipeline by C4X Discovery Ltd, H2 2014 36
Anxiety Disorders - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 37
Anxiety Disorders - Pipeline by Eisai Co., Ltd., H2 2014 38
Anxiety Disorders - Pipeline by Eli Lilly and Company, H2 2014 39
Anxiety Disorders - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 40
Anxiety Disorders - Pipeline by GW Pharmaceuticals plc, H2 2014 41
Anxiety Disorders - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H2 2014 42
Anxiety Disorders - Pipeline by Johnson & Johnson, H2 2014 43
Anxiety Disorders - Pipeline by Merz Pharmaceuticals GmbH, H2 2014 44
Anxiety Disorders - Pipeline by MI.TO. Technology S.r.L., H2 2014 45
Anxiety Disorders - Pipeline by Newron Pharmaceuticals S.p.A., H2 2014 46
Anxiety Disorders - Pipeline by Nuvo Research Inc., H2 2014 47
Anxiety Disorders - Pipeline by Omeros Corporation, H2 2014 48
Anxiety Disorders - Pipeline by Richter Gedeon Nyrt., H2 2014 49
Anxiety Disorders - Pipeline by Rottapharm SpA, H2 2014 50
Anxiety Disorders - Pipeline by Sigma-Tau S.p.A., H2 2014 51
Anxiety Disorders - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 52
Anxiety Disorders - Pipeline by Suda Ltd, H2 2014 53
Anxiety Disorders - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 54
Anxiety Disorders - Pipeline by Trevena, Inc., H2 2014 55
Assessment by Monotherapy Products, H2 2014 56
Number of Products by Stage and Target, H2 2014 58
Number of Products by Stage and Mechanism of Action, H2 2014 61
Number of Products by Stage and Route of Administration, H2 2014 64
Number of Products by Stage and Molecule Type, H2 2014 66
Anxiety Disorders Therapeutics - Recent Pipeline Updates, H2 2014 135
Anxiety Disorders - Dormant Projects, H2 2014 149
Anxiety Disorders - Discontinued Products, H2 2014 152
Anxiety Disorders - Discontinued Products (Contd..1), H2 2014 153
Anxiety Disorders - Discontinued Products (Contd..2), H2 2014 154

[List of Figures]
Number of Products under Development for Anxiety Disorders, H2 2014 14
Number of Products under Development for Anxiety Disorders - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 16
Number of Products under Investigation by Universities/Institutes, H2 2014 20
Comparative Analysis by Clinical Stage Development, H2 2014 21
Comparative Analysis by Early Stage Products, H2 2014 22
Assessment by Monotherapy Products, H2 2014 56
Number of Products by Top 10 Targets, H2 2014 57
Number of Products by Stage and Top 10 Targets, H2 2014 57
Number of Products by Top 10 Mechanism of Actions, H2 2014 60
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 60
Number of Products by Top 10 Routes of Administration, H2 2014 63
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 64
Number of Products by Top 10 Molecule Types, H2 2014 65
Number of Products by Stage and Top 10 Molecule Types, H2 2014 66

【掲載企業】

Ache Laboratorios Farmaceuticos S/A
Adamed Sp. z o.o.
Addex Therapeutics Ltd
Avineuro Pharmaceuticals, Inc.
Azevan Pharmaceuticals, Inc.
Beech Tree Labs, Inc.
Bionomics Limited
Boehringer Ingelheim GmbH
C4X Discovery Ltd
Concert Pharmaceuticals, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GW Pharmaceuticals plc
HolsboerMaschmeyer NeuroChemie GmbH
Johnson & Johnson
Merz Pharmaceuticals GmbH
MI.TO. Technology S.r.L.
Newron Pharmaceuticals S.p.A.
Nuvo Research Inc.
Omeros Corporation
Richter Gedeon Nyrt.
Rottapharm SpA
Sigma-Tau S.p.A.
SK Biopharmaceuticals Co., Ltd.
Suda Ltd
Sumitomo Dainippon Pharma Co., Ltd.
Trevena, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[不安障害(Anxiety Disorders):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆